top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 5 days ago
  • 1 min read

18/03/2026




























J&J announced FDA approval for icotrokinra for adult and pediatric patients with moderate to severe plaque psoriasis (Ref)


Johnson & Johnson announced that the US FDA had approved ICOTYDE™ (icotrokinra; IL-23 receptor antagonist) for the treatment of adults and pediatric patients aged 12 years and older who weighed at least 40 kg with moderate to severe plaque psoriasis

  • Icotrokinra met all primary efficacy endpoints and demonstrated a favorable safety profile across Phase 3 studies


  • The approval was backed by 5 Phase 3 studies (ICONIC program) which simultaneously evaluated ICOTYDE in adults and adolescents, high impact sites such as scalp and genital PsO, and in duplicate head-to-head trials versus an active comparator


    •  ICONIC-LEAD/ NCT06095115, ICONIC-TOTAL/ NCT06095102, ICONIC-ADVANCE 1/ NCT06143870, ICONIC ADVANCE-2/ NCT06220604, ICONIC-ASCEND/ NCT06934226




bottom of page